AMGN•benzinga•
Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year
Summary
Amgen's Uplizna met key endpoints in a Phase 3 gMG trial, showing sustained efficacy and improvement in muscle function with two doses a year.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 13, 2025 by benzinga